The purpose of this study is to identify an early indicator of drug efficacy in patients with advanced colorectal cancer - a prospective evaluation of circulating tumor cells, positron-emission tomography scan and RECIST criteria.
1. To determine if measuring both tumor metabolic response (via FDG-PET scan) \& circulating tumor cells (CirTC) at 4 weeks after starting treatment, is a better predictor of clinical outcome than measuring either modality alone in patients with metastatic colorectal cancer (CRC) who are undergoing first-line oxaliplatin-based chemotherapy. 2. To determine if a new method of assessing drug response (measuring tumor metabolic response via FDG-PET \& CirTC at 4 weeks after starting treatment) better predicts clinical outcome than the conventional method (measuring radiological changes in tumor dimensions at 10 weeks after starting treatment via the 'Response Evaluation Criteria in Solid Tumors' - RECIST).
Study Type
OBSERVATIONAL
Enrollment
84
The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy
Time frame: 2 years
Overall survival
Time frame: 4 years
Progression-free survival
Time frame: 4 years
serum carcinoembryonic antigen (CEA) level
Time frame: 4 years
Circulating tumor cells level changes at 4 weeks after chemotherapy
Time frame: 2 years
RECIST-based tumor response at 10 weeks after chemotherapy
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.